Prosecution Insights
Last updated: April 19, 2026

Examiner: YOUNG, MICAH PAUL

Tech Center 1600 • Art Units: 1618 1641

This examiner grants 55% of resolved cases

Performance Statistics

55.0%
Allow Rate
-5.0% vs TC avg
1018
Total Applications
+30.1%
Interview Lift
1297
Avg Prosecution Days
Based on 965 resolved cases, 2023–2026

Rejection Statute Breakdown

0.6%
§101 Eligibility
20.0%
§102 Novelty
55.3%
§103 Obviousness
9.7%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18252969 Liquid Composition Comprising Cereal Beta-Glucan or a Cereal Extract Comprising Beta-Glucan Non-Final OA Symrise AG
19176436 PHARMACEUTICAL COMPOSITIONS OF RIBOCICLIB Non-Final OA Novartis AG
17754059 RADIOLABELLED GRPR-ANTAGONIST FOR USE AS THERAGNOSTIC Final Rejection NOVARTIS AG
17850879 METHODS AND SYSTEMS FOR NONINVASIVE CONTROL OF BRAIN CELLS AND RELATED VECTORS AND COMPOSITIONS Final Rejection CALIFORNIA INSTITUTE OF TECHNOLOGY
18056599 Formulations for the Suprachoroidal Space of an Eye and Methods Final Rejection Georgia Tech Research Corporation
17700987 FLUORESCENT PROBES FOR MONOACYLGLYCEROL LIPASE (MAGL) Non-Final OA Hoffmann-La Roche Inc.
18011664 Methods For Reducing Catecholamine-Formaldehyde Adducts Non-Final OA Nevakar Injectables Inc.
18103932 IODINATED COMPOUNDS AND HYDROGELS FORMED FROM SAME Non-Final OA Boston Scientific Scimed, Inc.
17737229 INTRANASAL ADMINISTRATION OF GLUTAMATE CARBOXYPEPTIDASE (GCP-II) INHIBITORS Final Rejection The Johns Hopkins University
17475794 NON-FIBROUS FILM AND CELL SHEET Non-Final OA Industrial Technology Research Institute
18223714 LOADING OF HUMAN CAR T-CELLS WITH SUPERPARAMAGNETIC IRON-BASED PARTICLES FOR MAGNETIC TARGETING Non-Final OA FRIEDRICH-ALEXANDER-UNIVERSITÄT ERLANGEN-NÜRNBERG
18562744 RIGIDIFIED MACROCYCLES, COMPLEXES WITH RADIONUCLIDES, AND USE IN TARGETED RADIOTHERAPY OF CANCER Non-Final OA Cornell University
18042806 MRI CONTRAST MEDIUM INCLUDING CARBON-13-CONTAINING GRAPHENE QUANTUM DOT AND PREPARATION METHOD THEREFOR Non-Final OA SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION
18612007 Carrier Systems For Cannabinoids Non-Final OA Fertin Pharma A/S
17636107 IN VIVO IMMUNOIMAGING OF INTERLEUKIN-12 Non-Final OA Wayne State University
18116737 POLYMERS, SYSTEMS, AND METHODS FOR USING AND MONITORING POLYMERS FOR USE IN MEDICAL POLYMERS, IMPLANTS, AND PROCEDURES Final Rejection CANARY MEDICAL SWITZERLAND AG
16143678 PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION Non-Final OA AQUESTIVE THERAPEUTICS, INC.
17910199 COMPOSITIONS AND METHODS FOR NALOXONE DELIVERY Non-Final OA Purdue Pharma L.P.
18573077 Liquid Filled Capsule with Two Phase Liquid Fill Non-Final OA Lonza Greenwood LLC
17551289 VISCOSIFIED FLUIDS FOR MEDICAMENT DELIVERY Non-Final OA Palo Alto Research Center Incorporated
17769424 CONTROLLED RELEASE FORMULATIONS OF HIGHLY LIPOPHILIC PHYSIOLOGICALLY ACTIVE SUBSTANCES Final Rejection ADD Advanced Drug Delivery Technologies Ltd.
17760854 METHODS OF DETECTING NEUROLOGICAL DISORDERS VIA BINDING TO PHOSPHORYLATED TAU PROTEIN Non-Final OA Amydis, Inc.
18462235 METHODS AND COMPOSITIONS FOR DELIVERING MYCOPHENOLIC ACID ACTIVE AGENTS TO NON-HUMAN MAMMALS Non-Final OA Okava Pharmaceuticals, Inc.
18002511 TOPICAL PHARMACEUTICAL COMPOSITIONS Final Rejection Dermavant Sciences GmbH
18317360 PHARMACEUTICAL COMPOSITION AND METHOD FOR PREVENTION AND TREATMENT OF HEARING LOSS Final Rejection PHARMAZZ, INC.
18254904 SKIN-CLEANSING PRODUCT AND METHOD FOR OBTAINING SAID PRODUCT Non-Final OA ECZACIBASI TUKETIM URUNLERI SANAYI VE TICARET ANONIM SIRKETI
17611929 RADIOTHERAPEUTIC MICROSPHERES Final Rejection PLUS THERAPEUTICS, INC.
18252012 ENHANCED UPTAKE TRANSMUCOSAL DRUG DELIVERY COMPOSITIONS AND METHODS OF USE Non-Final OA Padagis Israel Pharmaceuticals Ltd.
18009699 IMAGING COMPOUNDS SELECTIVE FOR NaV1.7 Non-Final OA MEMORIAL SLOAN KETTERING CANCER CENTER
17836902 COMPOSITION OF N-PALMITOYL-ETHANOLAMIDE AND BAICALEIN IN CO-MICRONIZED FORM Final Rejection EPITECH GROUP S.P.A.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month